ENTITY

Basilea Pharmaceutica Ag (BSLN SW)

56
Analysis
Health CareSwitzerland
Basilea Pharmaceutica AG operates as a biopharmaceutical company. The Company focuses on the research, development, and commercialization of products targeting the medical challenge of resistance and non-response to current treatment options for fungal infections, bacterial infections, and cancer.
more
15 Aug 2024 19:10Issuer-paid

Basilea Pharmaceutica - Poised for an eventful H224

Basilea’s H124 results reflect strong momentum across its pipeline and we expect the pace to accelerate in H224. The key highlight of the period...

Share
22 Jun 2024 01:10Issuer-paid

Basilea Pharmaceutica - Final oncology asset (lisavanbulin) divested

Basilea Pharmaceutica has announced an asset purchase agreement with the Glioblastoma Foundation for lisavanbulin (BAL101553), the remaining drug...

Share
18 May 2024 13:10Issuer-paid

Basilea Pharmaceutica - Cresemba milestone payments continue to roll in

Basilea Pharmaceutica has announced the triggering of a US$1.25m milestone payment from Pfizer, triggered by sustained strong sales of Cresemba in...

Share
23 Apr 2024 01:10Issuer-paid

Basilea Pharmaceutica - Need for innovation against severe infections

At its recent capital markets day (CMD) and with the support of key opinion leaders, Basilea highlighted the rising need for innovative therapies...

Share
10 Apr 2024 19:10Issuer-paid

Basilea Pharmaceutica - CARB-X grant for preclinical programs

In the lead up to its capital markets day, Basilea Pharmaceutica announced it has received initial funding of up to US$0.9m through a grant from...

Share
x